GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now
GSK plc (NYSE: GSK) heads into December 2025 as one of the stronger-performing big pharma names, with the share price hovering just below a 52‑week high after a year of earnings beats, upgraded guidance, revived cancer assets and a looming CEO handover. The U.S. ADR last traded at about $47.9 (close on 28 November), with a 52‑week range of roughly $31.7–$48.7, a market cap near $95.5 billion, and a trailing P/E around 13.3.MarketBeat Several sources estimate GSK’s total return in 2025 at roughly 30–40%, far ahead of its sector, with Zacks noting a 29% year‑to‑date gain versus about 11% for